Wegovy® (semaglitude)

Wegovy® – Overview

 

  • Wegovy® is an obesity medication which has the active ingredient Semaglitude and is manufactured by Novo Nordisk.

 

  • Originally, Semaglitde was developed (and has been in the market for a number of years) and was prescribed for the treatment of Diabetes, under the brand name Ozempic.

 

  • (Some Doctors  already prescribe Ozempic “Off Label” – which means that although the drug is actually authorized for the treatment of Diabetes, Doctors prescribe it “off label” for the treatment of weight loss.

 

  • The maufacturer subsequently discovered that doubling the dosage levels  lead to significant weight reduction.

 

  • Wegogy® is  intended for adults with a body mass index greater than 30, or greater than 27 with an obesity-related medical condition (i.e. diabetes, high blood pressure, high cholesterol, sleep apnea) and as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management.

 

  • Wegovy works by helping to regulate food intake and appetite. Wegovy is a human glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 analog) – it mimics the action of GLP-1 produced naturally by the gut, and to a lesser extent the pancreas and nervous system. GLP-1 targets areas of the brain that help to regulate appetite, especially after eating. It also slows how quickly the stomach empties, which makes you feel fuller for longer. In addition to this, Wegovy enhances the production of insulin. This is not all the information you need to know about Wegovy (semaglutide) for safe and effective use and does not take the place of your doctor’s directions. Review the full product information and discuss this information and any questions you have with your doctor or other health care provider.

 

  • In trials, patients taking Wegovy® lost about 15% of their body weight on average, with a third of patients losing more than 20 per cent.

 

  • This is a drug treatment which is intended to continue for the rest of a patient’s life.

 

  • Research shows that patients who stop using these drugs regain most of their weight within 12 months . “One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss, with similar changes in cardiometabolic variables. Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health. Diabetes, Obesity and Metabolism – A Journal of Pharmacology and Therapeutics.

 

  • In the USA, a four-week course of Wegovy® has a list price of $1,349 a month.

 

  • In the UK, pharmacies will charge patients with private insurance or those paying out of their own pockets between £199  and £299  ($251-$377) for a month’s supply of Novo Nordisk’s weight-loss drug Wegovy®.

 

 

Wegovy - Dosing Schedule

Wegovy® - General Information

Wegovy® is a weight loss drug containing the active ingredient, semaglutide. It’s injected into the body once a week to help you lose weight. Wegovy® is thought to be an effective weight loss drug when used alongside a healthy, reduced-calorie diet and increased exercise.

The drug has recently been approved in the UK and is available now. It was approved in the USA in 2021.

Wegovy® essentially works by suppressing the appetite and regulating food intake. The active ingredient, semaglutide, mimics the action of the hormone that’s involved in regulating appetite. This means you feel fuller for longer and less hungry. This can help you to eat less and hopefully lose weight.

It works best when it’s taken at the same time as making lifestyle changes (healthier diet and increased exercise). In fact, around 85% of users lost at least 5% of their weight, compared to just 40% losing 5% when no lifestyle changes were made.

When Wegovy® is combined with a reduced calorie diet and increased exercise, a 68-week study has shown that:

 

  • Around 85% of people lost more than 5% of their body weight
  • 66% of people lost more than 10% of their body weight
  • 48% of people lost more than 15% of their body weight
  • 30% of people lost more than 20% of their body weight

 

This compares to just 60% of people losing 5% of their weight when taking Saxenda® along with a reduced calorie diet and physical activity counselling.  

Wegovy can be used by adults ages 18-75 who have:

  • A BMI of 30 or above
  • A BMI of 27 or above and you have a weight-related health condition such as:
  • Asthma
  • Cardiovascular disease
  • Depression
  • Fatty liver disease
  • Gallbladder disease
  • High blood pressure
  • History of certain cancers
  • Osteoarthritis or gout
  • PCOS
  • Sleep apnoea


You won’t be able to take Wegovy® if you:

  • Are over 75
  • Are pregnant or breastfeeding
  • Have liver, kidney or heart failure, an eating disorder or pancreatitis
    Are taking insulin, sulphonylureas or other weight loss drugs that work in the same way as Wegovy, e.g. Victoza.

You inject Wegovy® just once a week into your tummy, thigh or upper arm.

 

 

Wegovy® injections come in a variety of doses. Depending on where you are in your Wegovy® journey, you will need to take a different dose.

 

The dose is gradually increased to make sure you cope with any potential side effects until you get to a maintenance dose, this process is known as titration.

 

If all goes to plan and you can tolerate the treatment, the dosing schedule will be as follows:

 

  • Weeks 1-4:    0.25mg weekly
  • Weeks 5-8:   0.5mg weekly
  • Weeks 9-12:  1mg weekly
  • Weeks 13-16: 1.7mg weekly
  • Weeks 17 onwards:  2.4mg weekly

Wegovy® has been shown to be an effective weight loss treatment, when used alongside a reduced-calorie diet and increased physical activity.  

In clinical trials=around 85% of people lost more than 5% of their body weight when using Wegovy and following a reduced-calorie diet and increased exercise plan:  

 

  • Around 85% people lost at least 5% of their starting body weight after 6 months.

 

  • Around 66% people lost more than 15% of their starting body weight after one year 

Like all medications, some people might feel some side effects from taking Wegovy®. It’s thought that more than one in 10 people might experience headaches, vomiting, diarrhoea, constipation, tummy ache or nausea. 

 

Some people might also experience dizzy spells, indigestion and bloating among other symptoms. Find out more by reading the patient information leaflet here.

Any Wegovy® pens that haven’t been opened should be kept in the fridge. During use you can keep the pens for 6 weeks in the fridge or room temperature (below 30°C).

 

Pens need to be disposed of in the sharps bin you’re given when you start your treatment. When you’re prescribed Wegovy® we’ll let you know how to get rid of the sharps bin and its contents.

  • Although made by the same manufacturer Wegovy® and Saxenda® are different. The main difference is how often you need to use them. You would need to inject Wegovy® once a week but Saxenda® needs to be injected daily.

 

  • They also contain different active ingredients. Wegovy® contains Semaglutide while Saxenda® contains Liraglutide. Yet, these work in similar ways to suppress your appetite to help you to lose weight

Wegovy can be used by adults ages 18-75 who have:

 

A BMI of 30 or above, or

 

A BMI of 27 or above and you have a weight-related health condition such as:

 

  • Asthma
  • Cardiovascular disease
  • Depression
  • Diabetes
  • Fatty liver disease
  • Gallbladder disease
  • High blood pressure
  • History of certain cancers
  • Osteoarthritis or gout
  • PCOS
  • Sleep apnoea 
  •  

You won’t be able to take Wegovy® if you:  

 

  • Are over 75
  • Are pregnant or breastfeeding
  • Have liver, kidney or heart failure, an eating disorder or pancreatitis
  • Are taking insulin, sulphonylureas or other weight loss drugs that work in the same way as Wegovy.

Ideally, Wegovy should be kept refrigerated between 36°F to 46°F( 2°C to 8°C). Wegovy can remain for up to 28 days at room temperature (46°F to 86°F, or 8°C to 30°C).

 

When traveling with Wegovy, keep Wegovy in its original carton and avoid exposing it to direct sunlight or extreme temperatures.

Wegovy - UK Costs

  • In the UK, the larest online pharmacy is charging between £199  and £299 for a month’s supply of Novo Nordisk’s weight-loss drug Wegovy.

 

  • 0.25mg £198.99
    0.5mg   £198.99
    1mg      £198.99
    1.7mg   £248.99
    2.4mg   £298.99

Early - and later-stage AOM persistence

Early- and later-stage persistence with anti-obesit ymedications: A retrospective cohort study (Obesity – March 2024 – Early‐ and later‐stage persistence with anti-obesity medications – A retrospective cohort study)

 

  • Objective: The study’s objective was to examine the percentage of patients with aninitial antiobesity medication (AOM) fill who were persistent with AOM at 3, 6, and12 months and to characterize factors associated with persistence at 12 months.

 

  • Methods: This retrospective cohort study used electronic health records fromJanuary 2015 to July 2023 in a large health system in Ohio and Florida and included adults with BMI≥30 kg/m2 who had an initial AOM prescription filled between 2015 and 2022.

 

  • Results: The authors identified 1911 patients with a median baseline BMI of 38 (IQR, 34–44). Over time, 44% were persistent with AOM at 3 months, 33% at 6 months, and 19% at 12 months. Across categories of AOM, the highest 1-year persistence was in patients receiving semaglutide (40%). Semaglutide (adjusted odds ratio [AOR]=4.26, 95% CI: 3.04–6.05) was associated with higher odds of 1-year persistence, and naltrexone-bupropion (AOR=0.68, 95% CI: 0.46–1.00) was associated with lower odds, compared with phentermine-topiramate. Among patients who were persistent at 6 months, a 1% increase in weight loss at 6 months was associated with 6% increased odds of persistence at year 1 (AOR=1.06, 95%CI: 1.03–1.09).

 

  • Conclusions:

 

  1. Later-stage persistence with AOM varies considerably based on the drug and the weight loss achieved.
  2. At 3 months 56% of the patients had stopped taking their AOM drugs; at 6 months 66% of patients had stopped taking their drugs; and at the end of Year 1, 81% of patients has stopped taking their drugs.
  3. Although later-stage persistence with AOM remains low, patients receiving the newer, more effective forms of AOM (semaglitude) and those experiencing greater medium-term weight loss are more likely to persist.
  4. Among privately insured individuals, there is also significant variation in AOM persistence based on insurance carrier.